Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

This article is part of a series on Biology and therapy of fibromyalgia, edited by Leslie Crofford.

Highly AccessReview

Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome

Dina Dadabhoy1 email, Leslie J Crofford2 email, Michael Spaeth3 email, I Jon Russell4 email and Daniel J Clauw5 email

1Northwest Rheumatology Specialists, Elk Grove Village, IL 60007, USA

2Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA

3Center for Clinical Rheumatology Research, 82166 Graefelfing/Munich, Germany

4Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

5Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA

author email corresponding author email

Arthritis Research & Therapy 2008, 10:211doi:10.1186/ar2443

Published: 8 August 2008

Abstract

Researchers studying fibromyalgia strive to identify objective, measurable biomarkers that may identify susceptible individuals, may facilitate diagnosis, or that parallel activity of the disease. Candidate objective measures range from sophisticated functional neuroimaging to office-ready measures of the pressure pain threshold. A systematic literature review was completed to assess highly investigated, objective measures used in fibromyalgia studies. To date, only experimental pain testing has been shown to coincide with improvements in clinical status in a longitudinal study. Concerted efforts to systematically evaluate additional objective measures in research trials will be vital for ongoing progress in outcome research and translation into clinical practice.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.